Objective-The EphB ligand ephrinB2 has been identified as a critical determinant of arterial endothelial differentiation and as a positive regulator of invading endothelial cells during angiogenesis. This study was aimed at identifying determinants of endothelial cell ephrinB2 expression. Methods and Results-Arteriovenous asymmetrical endothelial cell ephrinB2 expression in vivo is lost on transfer into culture with aortic endothelial cells becoming partially ephrinB2-negative and saphenous vein endothelial cells becoming partially ephrinB2-positive. Contact with smooth muscle cells and angiogenic stimulation by vascular endothelial growth factor lead to an increased endothelial cell ephrinB2 expression. Quiescent, smooth musclecontacting endothelial cells express ephrinB2 uniformly on their luminal surface. In contrast, monolayer endothelial cells translocate ephrinB2 to interendothelial cell junctions, which is strongly enhanced by EphB4-Fc-mediated receptor body activation. Junctional ephrinB2 colocalizes and coimmunoprecipitates with CD31. Conclusions-This study identifies distinct regulatory mechanisms of endothelial ephrinB2 expression and cellular distribution in quiescent and activated endothelial cells. The data demonstrate that endothelial cell ephrinB2 expression is controlled by microenvironmental determinants rather than being an intrinsic endothelial cell differentiation marker. 
T he Eph receptors comprise the largest family of receptor tyrosine kinases. 1 Their ligands, the ephrins, are membrane-associated molecules that are expressed as GPIanchored peripheral membrane molecules (ephrinA) or as transmembrane molecules (ephrinB). 1 B class ephrin ligands are capable of acting as signal-transducing molecules themselves, a process referred to as "reverse signaling." Originally, Eph receptors and ephrin ligands have been identified as neuronal guidance and tissue border-forming molecules. More recently, Eph and ephrin molecules have been shown to be expressed by a number of non-neural cells, including endothelial cells, intestinal epithelial cells, hematopoietic cells, and tumor cells. 2, 3 Genetic loss of function experiments in mice have revealed critical roles of EphB receptors and ephrinB ligands in early developmental vascular morphogenesis 4 -7 and in lymphangiogenesis. 8 Mice deficient in ephrinB2 or EphB4 have largely complementary phenotypes characterized by early embryonic lethality with disturbed arteriovenous differentiation. As such, ephrinB2 and EphB4, being asymmetrically expressed by arterial and venous endothelial cells, respectively, are not just markers of arteriovenous differentiation, but appear to be makers of proper arteriovenous assembly. 3 Endothelial cells (ECs) in the adult maintain their asymmetrical arteriovenous expression of ephrinB2 and EphB4, 9, 10 suggesting that the EphB/ephrinB system may play a role in controlling vascular homeostasis. Yet little is known about the regulation and function of endothelial EphB receptor and ephrinB ligand expression in the adult vasculature. Genetic lineage tracking experiments in zebrafish suggest that vascular ephrinB2 expression may be an intrinsic property of arterial ECs. 11 In contrast, embryonic artery to vein and vein to artery quail-chick grafting experiments have indicated that arteriovenous asymmetrical Eph-ephrin expression has some plasticity until midgestation when the arteriovenous transdifferentiation potential becomes more restricted. 12 Analysis of ephrinB2 expression in the adult vasculature indicates that angiogenic EC express ephrinB2, which has been considered as evidence that angiogenic EC may be of arterial origin or that angiogenesis is an arteriolizing process. 9, 10 Likewise, recent microarray experiments have shown that at least some traits of organ-specific and caliber-specific EC differentiation are maintained even on prolonged culture in vitro. 13 In turn, it is well-established that isolated EC rapidly lose their organ-specific and vessel caliber-specific properties on transfer into tissue culture, which suggests that microenvironmental cues may be required to maintain endothelial phenotypic differentiation. For example, shear stress has been identified as a major determinant of arteriovenous differentiation that affects endothelial ephrinB2 expression. 14, 15 Likewise, recent experiments in mice have shown that hypoxia controls ephrinB2 expression in endothelial cells. 16 Taken together, the recent literature provides evidence that arterial ephrinB2 expression is partially controlled by intrinsic genetic forces and in part by microenvironmental cues. To shed further light into the intrinsic versus microenvironmental regulation of arterial and angiogenic ephrinB2 expression, we have traced ephrinB2 expression in vivo and in vitro. We have also pursued manipulatory experiments in 2-dimensional and 3-dimensional EC culture and differentiation systems. The experiments demonstrate that arterial and angiogenic EC ephrinB2 expression is not an intrinsic property of distinct EC populations, but rather controlled by microenvironmental forces. Furthermore, the identification of luminal and intercellular junctional expression of ephrinB2 and the context-specific association of ephrinB2 with CD31 provide a strong rationale for specific functions of EC ephrinB2 in controlling vascular homeostasis and the trafficking of circulating cells.
Materials and Methods
For detailed methodology, please see http://atvb.ahajournals.org. Briefly, EC ephrinB2 expression in vivo and into culture was traced using reverse-transcription polymerase chain reaction (RT-PCR), in situ hybridization, Western blotting, immunocytochemistry, and immunohistochemistry. RT-PCR was performed as described previously. 17 In situ hybridizations were performed using sense and antisense probes corresponding to bp 7 to bp 1028 from NCBI sequence NM-004093. Immunoprecipitations were performed using EphB4-Fc receptor bodies coupled to Protein-G-agarose. EphrinB2 polyclonal antibodies (R&D Systems) were used for Western blotting experiments. Cytochemical and immunohistochemical detection of ephrinB2 protein in cells and tissue sections was performed using EphB4-Fc receptor bodies and polyclonal ephrinB2 antibodies as detecting probes.
EphrinB2 mRNA and protein expression was studied in tissues and cultured ECs. Paraffin-embedded tissue sections were processed according to standard immunohistochemical techniques and used for in situ hybridizations, as well as EphB4-Fc receptor body and ephrinB2 antibody staining. Cellular expression of ephrinB2 mRNA and protein expression were traced in standard monolayer culture, as well as in differentiated 3-dimensional spheroidal cell culture techniques as described previously. 18 Spheroidal EC culture included 3-dimensional coculture spheroids of EC and smooth muscle cells (SMCs), which mimic the spatial assembly of the physiological vessel wall in an inside-out orientation. 19 This technique was particularly used because it represents the hitherto most advanced cellular model of the quiescent EC phenotype. 19 
Results

Arteriovenous Asymmetrical EphrinB2 Expression In Vivo Is Lost on Transfer of ECs Into Culture
RT-PCR screening of different EC populations cultured in vitro showed that all analyzed EC populations, irrespective of their arterial or venous origin, express ephrinB2 mRNA ( Figure I , available online at http://atvb.ahajournals.org). To more closely compare the in vivo and in vitro ephrinB2 expression pattern of individual ECs, in situ hybridization experiments were performed on sections of human aortas and saphenous veins, as well as on human umbilical arteries and veins ( Figure 1 ). Corresponding to the reported mouse developmental arteriovenous asymmetrical expression pattern of ephrinB2, 9, 10 ECs in the adult human aorta are uniformly ephrinB2-positive ( Figure 1A ). In contrast, ECs in the saphenous vein do not express detectable levels of ephrinB2 mRNA ( Figure 1A) . ECs from the umbilical cord are the most frequently used human ECs studied in culture. We therefore assessed the expression of ephrinB2 by in situ hybridization in the human umbilical cord. Surprisingly, ephrinB2 shows no arteriovenous asymmetrical expression pattern in the vessels of the umbilical cord. ECs in both the umbilical artery and the umbilical vein are uniformly positive for ephrinB2 ( Figure 1B ).
Arterial and venous ECs lose their arteriovenous asymmetrical ephrinB2 expression pattern when they are removed from their microenvironment and cultured in vitro. EphrinB2 is expressed in subpopulations of all cultured EC populations independent of their arterial or venous origin ( Figure 1A , 1B), indicating that arteriovenous asymmetrical EC ephrinB2 expression is not an intrinsic property of arterial cells, but rather controlled by microenvironmental cues.
Contact With Smooth Muscle Cells as Well as Stimulation by VEGF Control Endothelial EphrinB2 Expression
Based on the above findings, we next analyzed environmental conditions that may control EC ephrinB2 expression. It has been shown that contact with SMCs controls differentiation of ECs 20, 21 and induces EC quiescence. 19 To analyze the capacity of SMC to modulate ephrinB2 expression in ECs, human umbilical vein endothelial cells (HUVECs) were cocultured with SMCs (human umbilical artery SMCs) in 3-dimensional EC/SMC coculture spheroids. Within these spheroids, ECs organize as surface monolayer enclosing a core of SMCs. 19 EphrinB2 expression was analyzed by in situ hybridization and immunofluorescence staining using In vivo experiments have shown that the upregulation of ephrinB2 in EC correlates with their angiogenic activation. 9, 10, 22 Because VEGF is one of the most potent and the most specific inducers of angiogenesis, we analyzed if VEGF stimulation induces ephrinB2 expression in HUVECs cultured as standard monolayer. Approximately 60% of unstimulated early-passage HUVECs express detectable amounts of ephrinB2 ( Figure 2B ). Stimulation of ECs with VEGF increases the number of ephrinB2-positive cells close to 100% ( Figure 2B ).
Polarized Quiescent ECs Express EphrinB2 on Their Luminal Surface
These experiments indicate that contact with SMCs controls the expression of EC ephrinB2. Based on these findings, we performed high-resolution double-labeling experiments for ephrinB2 and CD31 to gain insights into the subcellular localization of ephrinB2 in quiescent endothelial cells in vivo and in vitro (Figure 3 ). Analysis of cross-sections of the umbilical vein identified the primarily junctional localization of CD31 ( Figure 3A ) and the luminal expression of ephrinB2 ( Figure 3C and 3E) . Corresponding double-labeling experiments of differentiated EC/SMC coculture spheroids similarly demonstrated ephrinB2 staining on top of the junctional and abluminal CD31 staining in the quiescent surface EC layer ( Figure 3B , 3D, and 3F).
Eph-B4 Receptor Body Stimulation Induces the Junctional Translocation of EphrinB2
On confluence, ephrinB2-expressing HUVECs accumulate ephrinB2 at interendothelial cell junctions ( Figure 2B , lower right; Figure 4A ). Stimulation of confluent HUVEC monolayer with EphB4-Fc receptor bodies for 30 minutes leads to endocytosis of the resulting EphB4/ephrinB2 complex (Figure 4B versus 4A) , confirming the reported resolution of cell . A, HUVECs were grown in 3-dimensional spheroids either alone (EC) or in coculture with SMC (SMC). In the coculture model, SMCs form the multicellular core of the spheroid, which is covered by a monolayer of quiescent ECs. 19 Spheroids were embedded, sectioned, and probed for ephrinB2 expression by in situ hybridization (ISH-EB2) and immunocytochemistry (ICC-EB2). ECs in solo EC spheroids express barely detectable ephrinB2. In contrast, quiescent surface monolayer ECs grown in contact with SMCs become almost uniformly positive for ephrinB2. B, To study the regulation of EC ephrinB2 expression by VEGF, HUVECs were grown as confluent monolayer in the absence or presence of VEGF and probed for ephrinB2 mRNA expression by in situ hybridization (ISH-EB2) after pelleting, embedding, and sectioning. Correspondingly, confluent HUVEC monolayers were fixed and stained by immunocytochemistry (ICC-EB2) for ephrinB2 protein expression. Approximately 60% of monolayer cultured HUVEC express ephrinB2. In contrast, stimulation with VEGF induces prominent expression of VEGF with close to 100% of the cells expressing ephrinB2. Confluent monolayer HUVECs express ephrinB2 in a distinctly interendothelial junctional pattern. Scale bar, 50 m.
contact-dependent EphB4 -ephrinB2 interactions by endocytosis. 23, 24 To probe the requirement of reverse ephrinB2 signaling for receptor body-mediated ligand endocytosis, we stimulated HUVECs expressing cytoplasmically truncated ephrinB2 with EphB4-Fc receptor bodies. Deletion of the cytoplasmic domain of ephrinB2 prevents endocytosis of the EphB4/ephrinB2 complex. Instead, the resulting EphB4/⌬C-ephrinB2 complex translocates to cellular junctions ( Figure  4D versus 4C) . Based on these findings, we tested EphB4-Fc-mediated cellular ephrinB2 redistribution in porcine aortic endothelial cells (PAECs), which do not express endogenous ephrinB2. 25 Intriguingly, noncontacting subconfluent PAECs express ephrinB2 in a clustered manner at lamellipodial cell protrusions, likely reflecting the invasive and migratory phenotype of tip cells in angiogenic sprouts, 26 
CD31 Associates Context-Dependently With EphrinB2 in ECs
Based on the observed junctional translocation of ephrinB2 in confluent and particularly EphB4 receptor body-stimulated ECs, we performed colocalization experiments of ephrinB2 with the junctional molecule CD31. As shown in Figure 5 , CD31 ( Figure 5A ) and ephrinB2 ( Figure 5B ) colocalize at interendothelial junctions in contacting HUVECs ( Figure  5C ). Based on these findings, we performed coimmunoprecipitation experiments to examine if ephrinB2 and CD31 interact directly in endothelial cells. Immunoprecipitation of HUVECs and PAECs expressing full-length ephrinB2 (ephrinB2) or cytoplasmically truncated ephrinB2 (⌬C-ephrinB2) were stimulated for 30 minutes with EphB4-Fc after which monolayers were fixed and the cells stained for ephrinB2. Unstimulated HUVECs express ephrinB2 on their cell surface and at cell-cell contacts (A, C). Stimulation of full-length ephrinB2-expressing HUVECs with EphB4-Fc leads to endocytosis of the receptorligand complex (B, arrow). In contrast, ⌬C-ephrinB2-expressing cells are not capable to endocytose the receptor-ligand complex, but translocate ephrinB2 to interendothelial junctions (D). Similar effects were observed in PAECs. Yet, PAECs show only minimal receptor-ligand complex endocytosis (F, arrow). Instead, ephrinB2 translocates primarily to interendothelial junctions after EphB4-Fc stimulation (F), which is even more pronounced in ⌬C-ephrinB2-expressing PAECs (H). Scale bar, 50 m.
ephrinB2 from HUVECs followed by ephrinB2 Western blot identifies only a faint ephrinB2 band corresponding to the weak expression of ephrinB2 in unstimulated HUVECs ( Figure 4D, lane 1 ). Yet this weak ephrinB2 signal coprecipitated a prominent CD31 band ( Figure 4D, lane 1) . Stimulation of monolayer ECs with VEGF or coculture of HUVECs with SMCs in spheroids leads to a more intense ephrinB2 precipitation band ( Figure 5D, lanes 2 and 3) , confirming the observed positive regulation of EC ephrinB2 expression by contact with SMC ( Figure 2A ) and VEGF ( Figure 2B ). Precipitation of ephrinB2 from VEGF-stimulated HUVECs leads to prominent coprecipitation of CD31 ( Figure 5D, lane  2 ). Yet coculture of ECs with SMCs in 3-dimensional coculture spheroids leads to barely detectable CD31 coprecipitation with ephrinB2 ( Figure 5D, lane 3) . Coculture of ECs with SMCs in 3-dimensional spheroids mimics the quiescent EC phenotype. We therefore pursued ephrinB2/ CD31 coimmunoprecipitation experiments from ECs freshly scraped from intact umbilical cords. These in vivo-derived HUVECs express abundant ephrinB2 ( Figure 5D, lane 5 ). Yet these quiescent EC do not coprecipitate CD31.
To further validate and study the observed association of ephrinB2 and CD31, we pursued coimmunoprecipitation experiments with PAECs expressing full-length ephrinB2 and cytoplasmically truncated ephrinB2. As in HUVECs, ephrinB2-expressing PAECs coimmunoprecipitate CD31 with ephrinB2 ( Figure 5E , lane 1). Stimulation with EphB4-Fc leads to a transient increase of ephrinB2/CD31 complex formation ( Figure 5E, lanes 2 and 3) corresponding to the receptor body stimulated translocation of ephrinB2 to interendothelial cell junctions (Figure 4) . Surprisingly, ⌬C-ephrinB2-expressing PAECs show only barely detectable CD31 coimmunoprecipitation ( Figure 5E, lane 4 ). Yet intense association of ephrinB2 and CD31 is detectable in ⌬C-ephrinB2 PAEC on EphB4-Fc receptor body stimulation.
Discussion
EC expression of the EphB ligand ephrinB2 is required for embryonic vessel formation. EphrinB2-deficient mice are not capable to support proper arteriovenous differentiation and subsequently vessel assembly. 4 -7 These genetic studies have identified ephrinB2 as a molecular marker of arterial ECs that is expressed at the earliest onset of arterial vascular differentiation. Yet little is known about the role of ephrinB2 in the adult vasculature, even though it is well-established that the arteriovenous asymmetrical expression of ephrinB2 is maintained in the adult vasculature. 9, 10 Sustained arteriovenous asymmetrical expression of ephrinB2 in the adult vasculature could point to important homeostatic maintenance functions, for example by supporting the cross-talk between ECs and SMCs. Alternatively, endothelial ephrinB2 in adults could be involved in controlling interactions of circulating cells with the vessel wall. For example, several EphB receptors and ephrinB ligands have been shown to be involved in leukocyte and lymphocyte function. [27] [28] [29] Similarly, EphB/ephrinB interactions have been shown to regulate platelet aggregation. 30 To shed further light into the mechanisms controlling arteriovenous differentiation and to guide experiments on the functional role of vascular EphB/ephrinB interactions in adults, this study was aimed at exploring the expression of the arterial and angiogenic marker ephrinB2 in ECs. Using a combination of in vivo and ex vivo analytical and in vitro manipulatory techniques, the experiments have shown that: Figure 5 . Junctional colocalization and association of ephrinB2 and CD31. Fixed HUVEC monolayers were double-stained for CD31 (A) and ephrinB2 (B). CD31 and ephrinB2 colocalize at interendothelial cell junctions (C). D, Correspondingly, ephrinB2 was immunoprecipitated with EphB4-Fc from lysates of monolayer HUVECs (ϮVEGF), EC/SMC coculture spheroids, and in vivo HUVECs. Samples were analyzed by Western blot analysis. Coimmunoprecipitation (co-IP) of CD31 was analyzed by re-probing the blots with an antibody to CD31. Unstimulated HUVEC monolayers weakly express ephrinB2, which co-IPs CD31 (lanes 1 and 4) . VEGF stimulation upregulates ephrinB2, which similarly co-IPs CD31 (lane 2). Contact with SMCs also upregulates ephrinB2 expression, but co-IPed CD31 is barely detectable (lane 3). Corresponding to the reduced co-IP of CD31 in SMC-contacting EC/SMC coculture spheroids, ephrinB2 in freshly harvested HUVECs from the umbilical cord does not co-IP CD31 (lane 5). E, CD31 co-IPs with ephrinB2 in full length ephrinB2-expressing PAEC, but not in ⌬C-ephrinB2-expressing PAEC (lane 1 versus 4). Stimulation of ephrinB2-expressing PAEC with EphB4-Fc leads to prominent co-IP of CD31 and ephrinB2 in ⌬C-ephrinB2-expressing PAEC (lanes 5 and 6) and a transient enhancement of CD31 and ephrinB2 co-IP in full-length ephrinB2-expressing PAEC (lanes 2 and 3). Scale bar, 50 m.
(1) the asymmetrical arteriovenous expression of ephrinB2 in vivo is lost on transfer into culture; (2) contact with SMCs (quiescent phenotype) and stimulation with VEGF (angiogenic activation) upregulate ephrinB2 expression in ECs; (3) quiescent resting ECs express ephrinB2 on their luminal cell surface; (4) ephrinB2 accumulates at interendothelial cell junctions on EphB4 receptor body activation; and (5) junctional ephrinB2 associates with CD31.
The findings of this study are likely to have important functional and conceptual implications. First, adding to the complexity of intrinsic versus microenvironmental endothelial cell phenotypic regulation, the present study has shown that ECs ephrinB2 expression is not an intrinsic determinant of the arterial EC phenotype, but rather needs to be maintained by local microenvironmental cues. Arteriovenous differentiation has been characterized as a primarily genetically driven process during development. 11, 31 Correspondingly, gene array experiments have shown that cultured ECs maintain some traits of their original vascular bed even when maintained in culture for prolonged periods of time. 13 In turn, it is well-established that organ-specific and caliber-specific EC differentiation and phenotypic heterogeneity is also under microenvironmental control. 32, 33 In line with these findings, the present study has demonstrated that the expression of the developmental arterial marker ephrinB2 in the adult must be maintained by local microenvironmental cues.
Second, the search for microenvironmental factors that control EC ephrinB2 expression identified contact with SMCs and stimulation by VEGF as strong positive regulators of ephrinB2 expression. These findings suggest that constitutive arterial and activation-associated angiogenic EC expression of ephrinB2 may be 2 mechanistically related, albeit functionally and temporally different, ephrinB2 expression states of the vascular endothelium. VEGF-mediated angiogenic activation is associated with ephrinB2 expression and an arteriolizing EC phenotype. 22, 34, 35 These findings correspond to cellular experiments demonstrating that EC ephrinB2 expression mediates invasive and propulsive signals which are compatible with a proangiogenic phenotype. 25 Conversely, the observed prominent regulation of ephrinB2 expression by contact with SMCs appears to reflect the quiescent arterial EC phenotype. This corresponds also to the recently observed prominent ephrinB2 expression in ECs of collecting lymphatic vessels that are in contact with SMCs. 8 Third, the present study has identified distinct spatial distribution pattern of EC ephrinB2. Quiescent cells in vivo and in a 3-dimensional spheroidal coculture model of ECs and SMCs that mimics many of the properties of the quiescent monolayer in vivo 19 express ephrinB2 in a strictly luminal expression pattern. In turn, confluent monolayer EC express ephrinB2 at intercellular junctions, which is enhanced by stimulation with EphB4-Fc receptor bodies. Prolonged stimulation with EphB4-Fc leads to endocytosis of the receptor-ligand complex, as has been reported during the EphB/ ephrinB-mediated termination of adhesion after contactmediated cell-cell repulsion. 23, 24 The luminal localization experiments of this study were limited to the umbilical cord and ECs cultured in EC/SMC coculture spheroids. Light microscopic analysis does not allow the precise dissociation of the luminal and the abluminal EC surface in most vascular bed with flattened EC. In turn, ultrastructural techniques and perfusion labeling techniques are not yet established to examine ephrinB2 expression in other vascular beds. It therefore remains to be demonstrated if ephrinB2 is luminally expressed in all ephrinB2-positive quiescent vascular beds. These will be critical experiments because the luminal expression of ephrinB2 in quiescent ECs would strongly imply EphB/ephrinB2 interactions in the control of circulating cell interactions with the vessel wall, as has recently been shown for the interaction of lymphocyte-expressed EphA receptors with high endothelial venule-expressed ephrinA1. 36 Correspondingly, EphB-expressing monocytes adhere preferentially to ephrinB2-expressing EC (D.P., unpublished results). EphB receptor body stimulation leads to junctional translocation of surface expressed EC ephrinB2. This may hint at a role of the EphB/ephrinB2 system in gating adherent cells to interendothelial cell junctions to prime them for transendothelial cell migration.
Fourth, a role of EC ephrinB2 in regulating the trafficking of adherent cells is also supported by the observation that junctional ephrinB2 associates with CD31. CD31 is an important adhesion molecule of ECs that has been shown to be involved in several signaling pathways that include the participation in the maintenance of adherens junction integrity and permeability, organization of the intermediate filament cytoskeleton, and regulation of catenin localization and transcriptional activities. 37, 38 The experiments have firmly established the association of CD31 with ephrinB2 in endothelial cells. Yet it remains to be seen if this is a direct interaction or if CD31 and ephrinB2 coimmunoprecipitate within a junctional complex that may involve other molecules such as VE-cadherin and VEGFR-2. Future work will be aimed at mechanistically dissecting the role of EC expressed ephrinB2 in controlling EC junctional organization, leukocyte recruitment, and leukocyte transmigration.
In summary, despite its inherently analytical nature, this study has shed important novel light into the regulation and possible roles of ECs expressed ephrinB2. EC ephrinB2 expression is under microenvironmental control (VEGF, contact with SMCs). Quiescent ECs express ephrinB2 on their luminal cell surface, from where it can be translocated to junctional complexes to associate with CD31. Collectively, these findings suggest important functions of the EphB/ ephrinB system in controlling vascular homeostasis.
